论文部分内容阅读
目的 :观察奥扎格雷治疗急性脑梗死的临床疗效及其安全性。方法 :81例经临床脑CT和 /或MRI扫描确诊为急性脑梗死患者 ,随机分成奥扎格雷治疗组 4 0例和东菱克栓酶对照组 4 1例 ,两组均于治疗前后 2周作神经功能缺损评分 ,结合治疗后患者的病残程度评定临床疗效 ,同时作凝血功能、血小板聚集和血粘度等检测。结果 :总有效率为 97.5 % ,与对照组相比无显著性差异 (P >0 .0 5 ) ,奥扎格雷对血小板聚集有显著抑制作用。结论 :静脉滴注奥扎格雷治疗急性脑梗死安全 ,有效。
Objective: To observe the clinical efficacy and safety of ozagrel in the treatment of acute cerebral infarction. Methods: Eighty-one patients diagnosed as acute cerebral infarction by clinical brain CT scan and / or MRI scan were randomly divided into two groups: 40 patients in ozagrel treatment group and 41 patients in control group. Neurological deficit score, combined with the patient’s degree of sickness after treatment to assess the clinical efficacy, at the same time for coagulation, platelet aggregation and blood viscosity and other tests. Results: The total effective rate was 97.5%, no significant difference compared with the control group (P> 0.05), and ozagrel significantly inhibited platelet aggregation. Conclusion: The intravenous infusion of ozagrel in the treatment of acute cerebral infarction is safe and effective.